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Abstract
Background: Epidemiological studies have provided enough evidence that genetic factors have an
important role in determining susceptibility to IBD. The most significant finding in the IBD research
has been identification of mutations in the gene that encodes Nod2 (nucleotide-binding
oligomerization domain 2) protein in a subgroup of patients with Crohn's disease. However, a very
similar gene encoding Nod1 protein still has not been well documented for its association with
Ulcerative colitis patients. Detection of polymorphism in NOD1 gene using SNP analysis has been
attempted in the present study. We evaluated frequency and significance of mutations present in
the nucleotide-binding domain (NBD) of NOD1 gene in context to Indian population.
Methods:  A total of 95 patients with ulcerative colitis and 102 controls enrolled in the
Gastroenterology department of All India Institute of Medical Sciences, New Delhi were screened
for SNPs by DHPLC and RFLP techniques. Exon 6 locus in the NBD domain of NOD1 gene was
amplified and sequenced. Genotype and allele frequencies of the patients and controls were
calculated by the Pearson's χ2 test, Fisher's exact test and ANOVA with Bonferroni's correction
using SPSS software version 12.
Results: We have demonstrated DHPLC screening technique to show the presence of SNPs in
Exon 6 locus of NBD domain of NOD1 gene. The DHPLC analysis has proven suitable for rapid
detection of base pair changes. The data was validated by sequencing of clones and subsequently
by RFLP analysis. Analyses of SNP data revealed 3 significant mutations (W219R, p = 0.002; L349P,
p = 0.002 and L370R, p = 0.039) out of 5 in the Exon 6 locus of NBD domain of the gene that
encompasses ATP and Mg2+binding sites. No significant association was observed within different
sub phenotypes.
Conclusion: We propose that the location of mutations in the Exon 6 spanning the ATP and Mg2+
binding site of NBD in NOD1 gene may affect the process of oligomerization and subsequent
function of the LRR domain. Further studies are been conducted at the protein level to prove this
possibility.
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Background
Two diseases grouped under idiopathic bowel inflamma-
tion are ulcerative colitis (UC) and Crohn's disease (CD).
Both diseases can be distinguished according to the differ-
ences in the clinical-pathological features [1]. The envi-
ronmental factors and genetic predispositions participate
in the emergence of the disease [2]. Several IBD linkage
regions were identified in genome wide linkage scans [3].
Both CD and UC are considered complex genetic traits, as
inheritance does not follow any simple Mendelian model
[3]. The discovery of mutations in the NOD2/CARD15
gene (the first susceptibility gene known for CD associ-
ated mainly with an ileal involvement) in western Euro-
pean and north American countries as well as in Hungary
was striking [4,5]. However, patient-control studies of Jap-
anese, Chinese, Korean and Turkish populations did not
encounter  NOD2/CARD15  polymorphisms either in
patients or control groups [6-10]. Nonsynonymous SNP
scan for ulcerative colitis identified a previously unknown
susceptibility locus at ECM1 and showed that several risk
loci were common to ulcerative colitis and Crohn's dis-
ease (IL23R, IL12B, HLA, NKX2-3 and MST1), whereas
autophagy genes ATG16L1 and IRGM along with NOD2
were specific for Crohn's disease [11].
Nod1 is a cytosolic protein and a member of a family of
proteins known as the NLR/Nod (CATERPILLER family)
[12]. Nod1 has been recognized as pattern-recognition
receptor (PRR). NOD1/CARD4 and is located on chromo-
some 7p14 that has been genetically linked to asthma
[13]. This protein family also includes a closely related
protein Nod2. Both Nod1 and Nod2 are thought to func-
tion in inflammation, innate and adaptive immunity as
well as in a variety of other processes that determine the
balance between health and disease. These proteins are
involved in recognition of intracellular bacteria primarily
through sensing glycopeptides derived from microbial
peptidoglycan. NLR family members are characterized as
centrally located oligomerization and nucleotide-binding
domain (NBD) that is followed by domain containing
multiple leucine rich repeats at the carboxy terminal and
caspase recruitment domain (CARD) at the amino termi-
nal end [14]. However, Nod2 contains two CARD domain
containing proteins [15]. Activation of Nod1 and Nod2
by ligand binding initiates a variety of cellular responses
including Nf-kB and MAPK activation, cytokine produc-
tion and apoptosis [16-18]. In the present study, we have
attempted to study SNP in NOD1 gene in ulcerative colitis
patients in order to determine if any significant mutation
is associated with ulcerative colitis. The analysis is based
on DHPLC technique which could screen accurately a
large number of samples within a short period of time.
The analysis was also validated by sequencing of PCR
products and PCR-RFLP analysis.
Methods
Patients and Healthy controls
The study group consisted of 95 unrelated patients of
Ulcerative colitis enrolled in the Gastroenterology depart-
ment of All India Institute of Medical Sciences, New
Delhi, India. 102 healthy controls matched for age and sex
were also evaluated. The control subjects were healthy vol-
unteers or patients with functional dyspepsia. They had
no gastrointestinal or liver diseases. The diagnosis of UC
was established according to clinical guidelines and crite-
ria based on endoscopic, radiological, and histopatholog-
ical examinations. The demographic and clinical features
of Ulcerative colitis patients are represented in Table 1.
Patients with UC were classified according to Montreal
Table 1: Demographic and clinical features of UC patient.
UC (n = 95)
Sex (M/F) 67/28
Duration of Disease, mean ± SD (range) 4.3 ± 3.92 (0.1-16)
Age at diagnosis (yr), mean ± SD 37 ± 12 (20-68)
15-40 66 (69.5%)
> 40 29 (30.5%)
Disease behaviour UC, n (%)
Remission 18 (18.9%)
Mild 40 (42.1%)
Moderate 28 (29.5)
Severe 9 (9.5)
Disease extent UC, n (%)
Rectum 46 (48.4%)
Left colon 27 (28.4%)
Pancolitis 22 (23.2%)
Smoking history
Yes 8 (8.4%)
No 82 (86.3%)
Ex 5 (5.3)
Family history of IBD y/n (%) 1/94 (1.05%)
Appendectomy y/n, n (%) 4/91 (4.2%)BMC Medical Genetics 2009, 10:82 http://www.biomedcentral.com/1471-2350/10/82
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classification for age at onset, disease extent and behavior
[19]. The mean age at diagnosis was 37 ± 12 years in UC
patients and the mean disease duration was 4.3 ± 3.92
years. All patients and healthy controls gave informed
consent and the study was approved by the ethical com-
mittee of the institute.
DNA extraction
1. Biopsy samples of patients
In the present study we have analyzed the genomic DNA
from biopsy samples of patients since a parallel study is
being carried out to study the gut bacteria profile during
disease conditions. Genomic DNA was extracted from the
colon biopsy samples (0.10 - 0.30 gm) according to the
modified protocol of Taggart [20]. Tissue pieces were
placed in 500 μl STE buffer (0.1 M NaCl, 0.05 M Tris-HCl
and 0.01 M EDTA, pH 8.0), 10 μl SDS 10%, and 30 μl pro-
teinase K (10 mg/ml). Solution was incubated at 50°C for
2 h for digestion. The tubes were inverted several times to
accelerate the digestion process. After the digestion proc-
ess was concluded, 3 μl of DNAse free RNAse was added,
and incubated for 30 min at 37°C. The resulting digestion
mixture was extracted once with 500 μl of buffer saturated
phenol, pH 8, once with phenol-chloroform-isoamyl
alcohol (24:1), and finally with chloroform-isoamyl alco-
hol. The DNA was then precipitated in 1 ml cold ethanol
and sodium acetate (3 M, NaOAc, pH 5.3) (Maniatis et al.,
1982). DNA pellets were dried and dissolved in 50 μl TE
buffer (1 mM Tris-HCl, 7.6 and 0.1 mM EDTA, pH 8.0).
2. Blood samples for controls
Genomic DNA was isolated for control individuals from
peripheral blood leucocytes following standard protocols
[21].
Detection of polymorphisms
1. DHPLC Analysis
Analysis of SNP was carried out using Denaturing High-
Performance Liquid Chromatography on a fully auto-
mated WAVE DNA fragment analysis system equipped
with a DNA Sep column (Transgenomic, Crewe, UK).
Prior to DHPLC analysis, PCR products from a reference
sample with known allele contribution were added in
equimolar amounts to PCR products from all patient sam-
ples, denatured at decreasing temperature from 95 to
65°C to allow hetero duplex formation and the mixtures
were automatically loaded onto the column with an
autosampler. At a critical denaturing temperature, homo-
and heteroduplexes were released off the column at differ-
ent times. PCR products were examined for heterodu-
plexes by subjecting 20 μl of each PCR product to a
denaturation step (10 min at 95°C) followed by gradual
re-annealing step by decreasing sample temperature from
95 to 65°C over a period of 45 min. The PCR products
were then separated (flow rate of 0.9 ml/min) through a
2% linear acetonitrile gradient and detected at 260 nm
absorbance. The start concentrations of buffer B were
selected by WaveMaker software version 4.1.40. (Transge-
nomic, Crewe, UK). The standard buffers were prepared
from concentrated tri ethyl ammonium acetate (TEAA,
100 ml Transgenomic Part No. 553301) to give Buffer A =
0.1 M TEAA and Buffer B = 0.1 M TEAA plus 25% Ace-
tonitrile. DNA was eluted with the following gradient con-
sisting of buffer A (0.1 mol/L tri ethyl ammonium acetate)
and buffer B (0.1 mol/L tri ethyl ammonium acetate con-
taining 250 mL/L acetonitrile): 60% A-40% B for 30 s;
50% A-50% B for 5.5 min; 25% A-75% B for 10 s; 5% A-
95% B for 1 min; and 60% A-40% B for 1.33 min. Wash
buffer was 8% Acetonitrile. Analysis of each amplified
sample took 8 min, including column regeneration and
equilibration. The oven temperatures for optimal hetero
duplex separation were determined using the WAVE
maker software version 4.1.40 (Transgenomic, Crewe,
UK), which gives a computer assisted determination of
melting profile and analytical conditions for each frag-
ment. The actual running temperature was established by
repeatedly injecting the sample 1-2°C below and above
the calculated temperature (64°C). Hetero duplex forma-
tion was checked by the melting profile of a known
sequence of Exon 6. The temperature giving 70 to 80%
double helical fraction of wild-type DNA was defined.
Positive controls were used to determine the DHPLC con-
ditions. A full list of primer sequence and annealing tem-
perature for PCR amplification, resolution temperature
and start concentrations of buffer B for DHPLC analysis
are listed in Table 2. PCR fragments spanning the ATPase
domain and Mg2+ binding site were amplified from all 95
patients and 102 control individuals and screened further
by DHPLC using the established gradient and temperature
conditions.
Table 2: Primer sequences and DHPLC analysis conditions for two sets of designed primers.
Exon Primer sequence (5'-3') Ampli. 
size(bp)
PCR anneal. 
temp.°C
DHPLC Oven 
temp.°C
Start % 
buffer B
N1Ex6-1 F 5' AGCAGGTATACCCAGCAGCTGC 3'
R 5' CCCGCTCTGGGTAGCAGTAGTG 3'
412 65.3 63.5 59-57
N1Ex6-2 F 5'CTACTGCTA CCAGAGCGGGA 3'
R 5'CCGGAAGATGATCCAGCAGAA 3'
427 55 64.5 59-57BMC Medical Genetics 2009, 10:82 http://www.biomedcentral.com/1471-2350/10/82
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2. Sequencing
The PCR products demonstrating differential DHPLC pro-
file were subsequently cloned in pGEMT vector and
sequenced on both strands to confirm the sequence varia-
tions. Sequencing reactions were performed with the ABI
big Dye Terminator cycle sequencing kit v1.1 (Applied
Biosystems, Foster City, CA, USA) and samples were
sequenced on an ABI Prism 310 Genetic Analyzer
(Applied Biosystems). The sequences were deposited to
the NCBI database.
3. RFLP analysis
In order to check the specificity of the DHPLC technique,
the samples screened by DHPLC were further subjected to
PCR-RFLP analysis. The PCR product of 840 bp (using
N1Ex6-1forward and N1Ex6-2 reverse primer) was
digested with Eco88I  and  SdaI  to resolve mutations of
E266K and L370R respectively. The PCR product of 427
bp (using N1Ex6-2 set of primers) was digested with MbiI
to resolve mutations of 4773delG and PCR product of 412
bp (using N1Ex6-1 set of primers) was digested with
Eco81I  to resolve mutation of W219R. The restriction
enzymes were procured from Fermentas. All the diges-
tions were run overnight at 37°C, electrophoresed on a
2% agarose gel, visualized under UV illumination and
stained with 0.4 mg/l ethidium bromide.
Statistical Analysis
Data was evaluated by SPSS software version 12 using
standard contingency χ2 tests or Fisher's Exact Test for cal-
culating Genotype frequency differences between cases
and controls. A two-tailed P-value < .05 was considered
significant. Hardy-Weinberg equilibrium was carried out
using Pearson's chi square test to determine whether the
proportion of each genotype obtained was in agreement
with expected values as calculated from allele frequencies.
Multiple comparisons were done using one way ANOVA
based on the conservative Bonferroni correction. The sig-
nificance level of α = .05 was chosen for all sets.
Results
Figure 1 represents the typical DHPLC chromatogram
showing SNP profile of NOD1 gene in Exon 6 locus of
NBD domain. The transitions observed in the ATP bind-
ing domain are represented in Figure 1B and Mg2+ binding
domain are shown in Figure 1C to 1F.
Homozygous nucleotide exchanges could be distin-
guished because of a slight shift in the elution time com-
pared to the reference. The addition of an approximately
equal amount of wild-type DNA to the sample (1:1)
before the denaturation step allows homozygous altera-
tions to be detected reliably. This step was taken for all the
samples to identify homozygous sequence variations so
that all the samples were analyzed first without mixing
with an equal amount of wild-type DNA to detect hetero-
zygous mutations. These were later confirmed by sequenc-
ing as shown in Figure 2. Table 3 represents the summary
of SNPs in Exon 6 of NOD1 gene. Amino acid substitution
from E266K was earlier observed by Walters et al, 2006 in
CD patients [22].
RFLP analysis using selected restriction enzymes further
confirmed the status of SNPs in our samples. Figure 3
shows representative results for genotyping of Exon 6
locus of NOD1 gene. To detect the nucleotide swap and to
reconfirm our DHPLC data, RFLP was used. The variants
were well distinguishable after restriction digestion (Fig-
ure 3). Transition of E266K (Figure 3A) could be detected
in homozygous wild type when digested with Eco88I gen-
erating three bands 424 bp, 303 bp and 113 bp (GG), the
mutated DNA was visible as a double band 727 bp and
113 bp (AA), whereas heterozygous type exhibited four
bands (GA). Transition of L370R was studied after digest-
ing the PCR product with SdaI. Wild-type (TT) yielded two
bands of 736 bp and 104 bp, single band of 840 bp in
homozygous mutated forms (GG), whereas heterozygous
forms (TG) yielded three bands (Figure 3B). In W219R
transition, three forms were resolved after digesting with
Eco81I. Single band of 412 bp was observed in wild type
(TT), two bands of 274 bp and 138 bp were observed in
homozygous condition (AA) whereas three bands were
observed as expected in heterozygous condition (TA) (Fig-
ure 3C). 4773delG mutation was detected after digesting
the PCR product with MbiI. Two bands of 331 bp and 96
bp sizes were observed in wild type (GG), the deleted
form was visible as a single band 427 bp due to missing of
a nucleotide at the restriction site, where as heterozygous
types yielded expected three bands (Figure 3D).
The genotypes and alleles distribution for NOD1 variants
in UC and controls are compared at different loci of Exon
6 (Table 4). No significant departures were noted from the
Hardy-Weinberg equilibrium (data not shown). Out of
five SNPs reported in this study, frequencies of transitions
fromW219R (p = 0.002); L349P (p = 0.002) and L370R (p
= 0.039) were found to be significant whereas previously
reported mutation of E266K did not show significant
result in our study group. Figure 4 represents a compre-
hensive list of mutations detected and their location in the
NOD1 gene. The nucleotide change T4644A leads to a
change in the amino acid W219R that is located in the
ATP binding site of the NBD domain whereas both L349P
and L370R mutations are located in the Mg2+ binding site
of the domain.
In order to establish any genotype/phenotype correlation,
genotype and allele frequencies of the following SNPs
were stratified by phenotypic sub groups. Analysis of the
allele and genotype frequencies of 4644T>A, 5035T>CBMC Medical Genetics 2009, 10:82 http://www.biomedcentral.com/1471-2350/10/82
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Representative results of NOD1 mutation profile identified in Mg2+ binding site and ATPase domain of Exon 6 by DHPLC anal- ysis Figure 1
Representative results of NOD1 mutation profile identified in Mg2+ binding site and ATPase domain of Exon 6 
by DHPLC analysis.
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DNA sequence electropherograms at exon6 locus from control and UC patients Figure 2
DNA sequence electropherograms at exon6 locus from control and UC patients. The nucleotide change is indi-
cated by an arrow.
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and 5098T>G in 95 UC cases at the Exon 6 locus showed
no association with age, gender, smoking history, and
appendectomy based on the Montreal classification
(Table 5). More specifically in case of 4644T>A, we
observed an increasing trend in the frequency of the A
allele in disease activity being lowest in cases of remission
(19.4%), 25% in moderate category, 26.2% in mild and
38.9% in severe category, however the differences did not
reach statistical significance. Similarly, in case of 5035T>C
SNP, we observed lowest frequency of disease extent in
rectum (1.5%) that increased to 22% in case of pancolitis
and 25% in case of left colon. The disease extent in case of
5098T>G being minimum (25.8%) in rectum followed by
32.1% in left colon and 38.2% in Pancolitis cases.
Discussion
This is the first report on the prevalence of the NOD1 pol-
ymorphisms in patients with Ulcerative colitis from
northern part of India. The DHPLC scanning procedure
described here has been found to be efficient and fast in
screening and detecting point mutations in the samples
including wild types as well as mutants. The sensitivity of
the procedure was determined by sequencing the PCR
products. We found this procedure well reproducible
since the pattern of DHPLC chromatograms matched well
with our expected sequencing data. This method has ear-
lier been used for detecting point mutations for factor IX
gene scanning [23] and other clinical applications [24].
We have successfully confirmed these results by RFLP
analysis.
In the course of the study, DNA from biopsy samples as
well as blood samples were analyzed since a parallel study
is being carried out to investigate the importance of com-
mensal bacterial flora and its communication strategies
with the host during IBD.
We did not observe any difference between quality of
DNA from colon biopsy samples versus blood. Several
lines of evidence suggest that poorly regulated activation
of the innate immune system could result in chronic
inflammatory diseases. Mutations in domain NBD and
Table 3: Summary of Mutations in Exon 6 of the NOD1 Gene
Patient No. mRNA mutation Amino acid substitution SubSNP (ss) Predicted protein product References
33 4644T>A W219R ss104807147 Normal size This report
4 4773delG - Aa261;PTC295 This report
16 4785G>A E266K ss104807137 Normal size Walters et al., 2006
25 5035T>C L349P ss104807141 Normal size This report
7 5098T>G L370R ss104807139 Normal size This report
Nucleotide numbering is based on NOD1 gene available with GeneBank accession no. AF149774. The first base of the initiator methionine is taken 
as the start of the cDNA (PTC = premature termination codon at specified amino acid residue, aa = amino acid, E = Glutamic acid, K = Lysine, P = 
Proline, L = Leucine, R = Arginine, W = Tryptophan). ss represents the accession nos. of SNPs submitted to NCBI database.
NOD1 E266K, L370R, W219R and 4773delG genotypes were  deduced from the migration profile on a 1.5% agarose gel Figure 3
NOD1 E266K, L370R, W219R and 4773delG geno-
types were deduced from the migration profile on a 
1.5% agarose gel. A. Wild-type DNA is visible as three 
bands 424 bp, 303 bp and 113 bp (GG), the mutated DNA is 
visible as double bands 727 bp and 113 bp (AA), where as 
heterozygotes show four bands (GA). B. Wild-type DNA vis-
ible as two bands 736 bp and 104 bp (TT), the mutated DNA 
is visible as a single band 840 bp (GG), where as heterozy-
gotes exhibit three bands (TG). C. Wild type DNA is visible 
as a single band 412 bp (TT), the mutated DNA as double 
bands 274 bp and 138 bp (AA), whereas heterozygotes show 
three bands (TA). D. Wild-type DNA is visible as two bands 
331 bp and 96 bp (GG), the deleted DNA is visible as a single 
band 427 bp (--), Heterozygotes are represented by three 
bands (G-). Lane M is a molecular weight marker of 100 bp 
(Fermentas).
4773delG
M      GG      G- --
E266K L370R
M       GG     GA     AA M        TT      TG     GG
W219R
M       TT      TA       AA
727bp
424bp
303bp
113bp
840bp
736bp
104bp
412bp
274bp
138bp
427bp
331bp
96bp
A. B.
C. D.BMC Medical Genetics 2009, 10:82 http://www.biomedcentral.com/1471-2350/10/82
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NOD1 gene with Exons and Introns Figure 4
NOD1 gene with Exons and Introns. Location of SNPs in Exon 6 are shown by arrows.
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Table 4: Genotypes and alleles distribution for NOD1 variants in UC and Controls
total Wild-type Heterozygous Homozygous Minor allele frequency OR1 95% CI1 P2
UC vs. control
Patients
4644T>A W219R
UC 95 61(64.2) 19(20.0) 15(15.8) 26
Controls 102 89(87.3) 7(6.9) 6(5.9) 9 3.960 1.569-9.995 0.002*
4773delG
UC 95 72(75.8) 15(15.8) 8(8.4) 16
Controls 102 87(85.3) 10(9.8) 5(4.9) 10 1.853 0.900-3.812 0.091
4785G>A E266K
UC 95 53(55.8) 27(28.4) 15(15.8) 30
Controls 102 68(66.7) 24(23.5) 10(9.8) 22 1.443 0.748-2.784 0.272
5035T>C L349P
UC 95 74(77.9) 12(12.6) 9(9.5) 16
Controls 102 55(53.9) 29(28.4) 18(17.6) 32 0.308 0.144-0.656 0.002*
5098T>G L370R
UC 95 55(57.9) 19(20.0) 21(22.1) 32
Controls 102 67(65.7) 24(23.5) 11(10.8) 23 2.326 1.033-5.238 0.039*
1ORs and probability values at 95% CI for disease status are shown.
2p-values were calculated with the Fisher's Exact test when comparing controls and UC patients.
P values refer to the UC vs. controls. *showing significant P value.B
M
C
 
M
e
d
i
c
a
l
 
G
e
n
e
t
i
c
s
 
2
0
0
9
,
 
1
0
:
8
2
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
3
5
0
/
1
0
/
8
2
P
a
g
e
 
9
 
o
f
 
1
1
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Table 5: Genotype and allele frequencies of 4644T>A, 5035T>C and 5098T>G SNPs in UC cases stratified by phenotypic subgroups, (n)
SNP/gene ss104807147 4644T>A ss104807141 5035T>C ss104807139 5098T>G
genotype TT (61) TA (19) AA (15) Total 
(95)
Freq(A) 
0.257
TT (74) TC (12) CC (9) Total 
(95)
Freq(C) 
0.157
TT (55) TG (19) GG (21) Total 
(95)
Freq(G) 
0.321
Sex
Male 40 16 11 67 0.283 52 10 5 67 0.149 35 15 17 67 0.365
Female 21 3 4 28 0.196 22 2 4 28 0.178 20 4 4 28 0.214
Age at 
diagnosis (yr)
15-40 41 15 10 66 0.265 50 9 7 66 0.174 38 12 16 66 0.333
> 40 20 4 5 29 0.241 24 3 2 29 0.121 17 7 5 29 0.293
Disease activity
Remission 13 3 2 18 0.194 13 3 2 18 0.194 13 2 3 18 0.222
Mild 25 9 6 40 0.262 33 3 4 40 0.138 22 10 8 40 0.325
Moderate 18 6 4 28 0.25 23 3 2 28 0.125 14 6 8 28 0.393
Severe 5139 0 . 3 8 9 531 9 0 . 2 7 8 61290 . 2 7 8
Disease extent
Rectum 17 9 7 33 0.348 32 1 0 33 0.015 21 7 5 33 0.258
Left colon 18 4 6 28 0.286 19 4 5 28 0.25 16 6 6 28 0.321
Pancolitis 26 6 2 34 0.147 23 7 4 34 0.221 18 6 10 34 0.382
Smoking 
history
Yes 4408 0 . 2 5 602 8 0 . 2 5 52180 . 2 5
No 54 13 15 82 0.262 63 12 7 82 0.159 46 17 19 82 0.335
Ex 3205 0 . 2 500 5 040150 . 2
Appendectomy
Yes 2114 0 . 3 7 5 400 4 021140 . 3 7 5
No 59 18 14 91 0.252 70 12 9 91 0.165 53 18 20 91 0.319BMC Medical Genetics 2009, 10:82 http://www.biomedcentral.com/1471-2350/10/82
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LRRs of NOD2 gene are frequently observed in patients
with Crohn's disease [7,25,26]. So far, association of
NOD1 gene with ulcerative colitis patients has not been
documented. We have chosen the Exon 6 spanning the
NBD domain of NOD1 gene for our study. Earlier studies
have shown that mutations within the exon encoding the
nucleotide-binding domain in the CATERPILER gene fam-
ily are associated with hereditary periodic fevers character-
ized by constitutive IL-1β production [27]. The
CATERPILLER protein cryopyrin/NALP3 regulates IL-1β
processing by assembling the multimeric inflammasome
complex that is regulated by binding with ATP [27,28].
Mutation of the nucleotide-binding domain might affect
ATP binding that may change the function of the follow-
ing processes like caspase-1 activation, IL-1β production,
cell death, macromolecular complex formation, self-asso-
ciation and association with the inflammasome compo-
nent.
The mutation E266K in the NOD1 gene observed in the
Exon 6 region was not significant (P = 0.272) in ulcerative
colitis patients of Indian origin when compared with the
non IBD population. However, this polymorphism has
earlier been reported to be significantly associated with
Crohn's disease susceptibility [5]. Although studied on a
limited number of samples our data shows that this geno-
type does not demonstrate any association with ulcerative
colitis. However new SNPs detected by us located in the
Mg2+ binding domain of the protein were L370R (P  =
0.039) and L349P (P = 0.002). The third significant muta-
tion was observed in the ATP binding domain of the gene,
W219R (P  = 0.002). These mutations are so far not
reported in UC patients. The genomic organization dem-
onstrates a high degree of conservation of the NBD- and
LRR encoding exons and all the predicted NBD/LRR pro-
teins are likely Mg2+ and ATP binding proteins [29,30].
These domains play an important role in the oligomeriza-
tion process thus any mutation in the ATP binding
domain would lead to a defective oligomerization process
due to non-availability of ATP required for this process.
Deletion of G at 4773 position causing a frame-shift
mutation observed in few Ulcerative colitis patients
though not in a significant population, but can be pre-
dicted as a potential locus that give rise to a pre-termina-
tion codon at 295 position of the amino acid encoding a
truncated protein that may affect the function of NOD1
gene considerably. Interestingly, we observed and
recorded that the patients showing this variant exhibited
symptoms of acute inflammation.
We have not found any significant association between
the different genotypes and the demographic data on the
patients or the clinical characteristics of UC though there
was an increasing trend in frequency of 5035T>C variant
allele in the disease extent from rectum to pancolitis and
left colon without significant association with any sub-
phenotypes.
Certain limitations of our data like limited size of the
samples must be considered when we are interpreting our
data. Before, we can make a firm conclusion on associa-
tion of these mutations with the disease, there is a need
for replication in an independent cohort. Given the
importance of these results, further confirmatory studies
are warranted in larger UC population.
Conclusion
Screening of samples for SNP analysis using DHPLC tech-
nique has been quite useful and less time consuming in
analyzing large number of patients samples. This high-
throughput genotyping technique is particularly suitable
for routine diagnosis of SNPs.
Our study confirms association of three SNPs to ulcerative
colitis. Significant mutations observed in ATP (W219R, p
= 0.002) and Mg2+ (L370R, p = 0.039 and L349P, p =
0.002) binding domains of Exon 6 may lead to a defective
oligomerization of protein which subsequently may lead
to a 'loss of function' by preventing the recognition of
MDP that is necessary for subsequent NF-kB activation
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